| Attributes | Values |
|---|
| rdf:type
| |
| description
| - videnskabelig artikel (da)
- article científic (ca)
- articol științific (ro)
- articolo scientifico (it)
- artigo científico (gl)
- artigo científico (pt)
- artigo científico (pt-br)
- artikull shkencor (sq)
- artículo científico (es)
- bilimsel makale (tr)
- scienca artikolo (eo)
- vedecký článok (sk)
- vetenskaplig artikel (sv)
- vitenskapelig artikkel (nb)
- vitskapeleg artikkel (nn)
- vědecký článek (cs)
- wetenschappelijk artikel (nl)
- wissenschaftlicher Artikel (de)
- научная статья (ru)
- научни чланак (sr)
- מאמר מדעי (he)
- artikel ilmiah (id)
- bài báo khoa học (vi)
- article scientifique (fr)
- বৈজ্ঞানিক নিবন্ধ (bn)
- artículu científicu espublizáu en 2012 (ast)
- наукова стаття, опублікована в лютому 2012 (uk)
- scientific article published on 16 February 2012 (en)
- scientific article published on 16 February 2012 (en-ca)
- scientific article published on 16 February 2012 (en-gb)
- مقالة علمية نشرت في 16 فبراير 2012 (ar)
|
| publication date
| |
| publication date
| |
| author name string
| |
| author name string
| - William S Weintraub
- Andrew M Tershakovec
- Arvind K Shah
- Mary E Hanson
- Jianxin Lin
- Robert S Lowe
|
| rdfs:label
| - Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials. (en)
- Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials. (nl)
- Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials. (ast)
|
| skos:prefLabel
| - Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials. (en)
- Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials. (nl)
- Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials. (ast)
|
| name
| - Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials. (en)
- Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials. (nl)
- Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials. (ast)
|
| author
| |
| author
| |
| title
| |
| title
| - Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials (en)
|
| page(s)
| |
| page(s)
| |
| instance of
| |
| instance of
| |
| PubMed ID
| |
| PubMed ID
| |
| PubMed ID
| |
| published in
| |
| published in
| |
| issue
| |
| volume
| |
| issue
| |
| volume
| |
| DOI
| |
| DOI
| |
| DOI
| - 10.1016/J.ATHEROSCLEROSIS.2012.02.016
|
| is about
of | |
| is cites work
of | - Residual macrovascular risk in 2013: what have we learned?
- Monitoring of lipids, enzymes, and creatine kinase in patients on lipid-lowering drug therapy
- Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II t
- Effect of naturally random allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease mediated by polymorphisms in NPC1L1, HMGCR, or both: a 2 × 2 factorial Mendelian randomization study
- The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management
- Dyslipidemia in type 2 diabetes: prevalence, pathophysiology, and management
- Secondary stroke prevention
- Effect of Low-Density Lipoprotein Cholesterol Lowering by Ezetimibe/Simvastatin on Outcome Incidence: Overview, Meta-Analyses, and Meta-Regression Analyses of Randomized Trials
- Clinical implications of the IMPROVE-IT trial in the light of current and future lipid-lowering treatment options
- Hepatitis C virus, cholesterol and lipoproteins--impact for the viral life cycle and pathogenesis of liver disease
- Ezetimibe therapy: mechanism of action and clinical update
- Efficacy of combination of Ezetimibe 10 mg and rosuvastatin 2.5 mg versus rosuvastatin 5 mg monotherapy for hypercholesterolemia in patients with type 2 diabetes
- Cardiovascular diseases in China: Current status and future perspectives
- Ezetimibe Attenuates Atherosclerosis Associated with Lipid Reduction and Inflammation Inhibition
- Effects of ezetimibe added to statin therapy on markers of cholesterol absorption and synthesis and LDL-C lowering in hyperlipidemic patients
- Treatment of dyslipidemia and cardiovascular outcomes: the journey so far--is this the end for statins?
- Reduction of Vascular Inflammation, LDL-C, or Both for the Protection from Cardiovascular Events?
- Inflammatory markers and cardiometabolic diseases
- Influence of atherosclerosis-related risk factors on serum high-sensitivity C-reactive protein levels in patients with type 2 diabetes: Comparison of their influence in obese and non-obese patients
- A Clinical Guide to Combination Lipid-Lowering Therapy.
|
![[RDF Data]](/fct/images/sw-rdf-blue.png)
![[cxml]](/fct/images/cxml_doc.png)
![[csv]](/fct/images/csv_doc.png)
![[text]](/fct/images/ntriples_doc.png)
![[turtle]](/fct/images/n3turtle_doc.png)
![[ld+json]](/fct/images/jsonld_doc.png)
![[rdf+json]](/fct/images/json_doc.png)
![[rdf+xml]](/fct/images/xml_doc.png)
![[atom+xml]](/fct/images/atom_doc.png)
![[html]](/fct/images/html_doc.png)